دورية أكاديمية
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study.
| العنوان: | Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study. |
|---|---|
| المؤلفون: | Dalle, Stéphane, Mortier, Laurent, Corrie, Pippa, Lotem, Michal, Board, Ruth, Arance, Ana María, Meiss, Frank, Terheyden, Patrick, Gutzmer, Ralf, Buysse, Brian, Oh, Kelly, Brokaw, Jane, Le, T Kim, Mathias, Susan D, Scotto, Julie, Lord-Bessen, Jennifer, Moshyk, Andriy, Kotapati, Srividya, Middleton, Mark R |
| بيانات النشر: | Springer Science and Business Media LLC //dx.doi.org/10.1186/s12885-021-08032-y BMC Cancer |
| سنة النشر: | 2021 |
| المجموعة: | Apollo - University of Cambridge Repository |
| مصطلحات موضوعية: | Advanced melanoma, Ipilimumab, Overall survival, Quality of life, Real-world, Subsequent therapy, Adult, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Female, Follow-Up Studies, Humans, Immune Checkpoint Inhibitors, Male, Melanoma, Middle Aged, Prospective Studies, Radiosurgery, Skin Neoplasms, Survival Analysis, Treatment Outcome, Young Adult |
| الوصف: | Funder: This work was supported by Bristol Myers Squibb (no grant number is applicable). ; BACKGROUND: Ipilimumab has shown long-term overall survival (OS) in patients with advanced melanoma in clinical trials, but robust real-world evidence is lacking. We present long-term outcomes from the IMAGE study (NCT01511913) in patients receiving ipilimumab and/or non-ipilimumab (any approved treatment other than ipilimumab) systemic therapies. METHODS: IMAGE was a multinational, prospective, observational study assessing adult patients with advanced melanoma treated with ipilimumab or non-ipilimumab systemic therapies between June 2012 and March 2015 with ≥3 years of follow-up. Adjusted OS curves based on multivariate Cox regression models included covariate effects. Safety and patient-reported outcomes were assessed. RESULTS: Among 1356 patients, 1094 (81%) received ipilimumab and 262 (19%) received non-ipilimumab index therapy (systemic therapy [chemotherapy, anti-programmed death 1 antibodies, or BRAF ± MEK inhibitors], radiotherapy, and radiosurgery). In the overall population, median age was 64 years, 60% were male, 78% were from Europe, and 78% had received previous treatment for advanced melanoma. In the ipilimumab-treated cohort, 780 (71%) patients did not receive subsequent therapy (IPI-noOther) and 314 (29%) received subsequent non-ipilimumab therapy (IPI-Other) on study. In the non-ipilimumab-treated cohort, 205 (78%) patients remained on or received other subsequent non-ipilimumab therapy (Other-Other) and 57 (22%) received subsequent ipilimumab therapy (Other-IPI) on study. Among 1151 patients who received ipilimumab at any time during the study (IPI-noOther, IPI-Other, and Other-IPI), 296 (26%) reported CTCAE grade ≥ 3 treatment-related adverse events, most occurring in year 1. Ipilimumab-treated and non-ipilimumab-treated patients who switched therapy (IPI-Other and Other-IPI) had longer OS than those who did not switch (IPI-noOther and Other-Other). Patients with prior therapy who did not switch therapy ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | text/xml; application/pdf; application/zip |
| اللغة: | English |
| العلاقة: | https://www.repository.cam.ac.uk/handle/1810/323189Test |
| DOI: | 10.17863/CAM.70643 |
| الإتاحة: | https://doi.org/10.17863/CAM.70643Test https://www.repository.cam.ac.uk/handle/1810/323189Test |
| رقم الانضمام: | edsbas.38B1D7C |
| قاعدة البيانات: | BASE |
| DOI: | 10.17863/CAM.70643 |
|---|